Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

belantamab mafodotin, bortezomib, dexamethasone

Details

Files
Generic Name:
belantamab mafodotin, bortezomib, dexamethasone
Project Status:
Active
Therapeutic Area:
Previously treated multiple myeloma
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0379-000
Call for patient/clinician input closed:
Tumour Type:
Myeloma
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Belantamab mafodotin is indicated for the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Belantamab mafodotin is indicated for the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open07-Aug-24
Call for patient/clinician input closed07-Nov-24
Submission received19-Dec-24
Submission accepted10-Jan-25
Review initiated13-Jan-25
Draft CADTH review report(s) provided to sponsor for comment09-Apr-25
Deadline for sponsors comments22-Apr-25
CADTH review report(s) and responses to comments provided to sponsor30-May-25
Expert committee meeting (initial)11-Jun-25
Draft recommendation issued to sponsor-
Draft recommendation posted for stakeholder feedback-
End of feedback period-

Files

Patient and Clinician Group Input View PDF
Last Updated : January 17, 2025